How does an aesthetic practice decide whether to invest in body toning technologies? We asked several aesthetic physicians to share what they’ve learned about what differentiates the technologies and more.
It’s an exciting time for atopic dermatitis patients as many new treatment options are on the market and in the pipeline. But treatment doesn’t yet offer a cure and many patients continue to suffer with symptoms, including itch, psychosocial and quality-of-life issues, according to a recent paper.
Abnormalities in epidermal barrier integrity, affecting factors such as epidermal calcium gradients, filaggrin, cornified envelopes, desquamation of corneodesmosomes and skin lipids, may also influence epidermal barrier dysfunction, according to a recent review.
A novel gel formulation combining tretinoin 0.04% and clindamycin 1% using a controlled release microsphere delivery system effectively treats acne vulgaris without the skin irritation associated with topical tretinoin alone, according to recent data.
A wearable patch may soon be able to assess inflammatory biomarkers found in the sweat and interstitial fluid in individuals with atopic dermatitis to ultimately provide real-time information about their skin health.
Dermatology Times spoke with Andrew Alexis, M.D., about his more than 15-year impact to the care of patients with skin of color.
Chemical peels offer important advantages for treating melasma. Researchers offer insights from a review of recent advances in chemical peel treatments in melasma and acne.
Melasma responds well to oral and locally injected tranexamic acid treatments, but clinical results from topical tranexamic acid administration have been disappointing, researchers report. They examined efficacy of a co-enhancer as a method to deliver the treatment.
Lifestyle recommendations are a complex aspect of eczema care. There are many things within in a patient's control that can impact severity and dermatologists should try to help patients identify these, one expert says.
Novartis, Quest Diagnostics collaborate on free genetic mutation testing initiative, The Know Now BRAF program, for patients with stage III or stage IV melanoma.